The potential impact of a prophylactic herpes simplex vaccine

Expert Opinion on Emerging Drugs

Volumn 13, Issue 1, 2008, Pages 41-52

  Rupp, Richard ^a   Bernstein, David I ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Genital herpes; Herpes simplex virus; Perinatal herpes; Vaccine

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; FAMCICLOVIR; HERPES SIMPLEX VACCINE; VALACICLOVIR;

DEATH; DISEASE SEVERITY; DRUG MEGADOSE; GENITAL HERPES; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PAIN; PERINATAL INFECTION; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ANIMALS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HUMANS; SIMPLEXVIRUS;

EID: 41349121632     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.1.41     Document Type: Review

References (106)

1. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis 2002;186(Suppl 1):S3-28
2. Fleming DT, Mcquillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337(16):1105-11
3. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296(8):964-73
4. Stanberry LR, Rosenthal SL, Mills L, et al. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. Clin Infect Dis 2004;39(10):1433-8
5. Mertz GJ, Rosenthal SL, Stanberry LR. Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes? Sex Transm Dis 2003;30(10):801-2
6. Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 2004;11(Suppl 1):A2-3
7. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003;30(10):797-800
8. Rosenthal SL, Stanberry LR, Biro FM, et al. Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 1997;24(2):135-9
9. Koutsky LA, Stevens CE, Holmes KK, et al. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. N Engl J Med 1992;326(23):1533-9
10. Langenberg AG, Corey L, Ashley RL, et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999;341(19):1432-8
11. Sacks SL, Griffiths PD, Corey L, et al. HSV shedding. Antiviral Res 2004;63(Suppl 1):S19-26
12. Crespi CM, Cumberland WG, Wald A, et al. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect 2007;83(5):359-64
13. Auslander BA, Biro FM, Rosenthal SL. Genital herpes in adolescents. Semin Pediatr Infect Dis 2005;16(1):24-30
14. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis Suppl 1996;100:27-32
15. Kimberlin DW, Whitley RJ. Neonatal herpes: what have we learned. Semin Pediatr Infect Dis 2005;16(1):7-16
16. Nahmias AJ. Neonatal HSV infection Part II: Obstetric considerations - a tale of hospitals in two cities (Seattle and Atlanta, USA). Herpes 2004;11(2):41-4
17. Handsfield HH, Waldo AB, Brown ZA, et al. Neonatal herpes should be a reportable disease. Sex Transm Dis 2005;32(9):521-5
18. Schomogyi M, Wald A, Corey L. Herpes simplex virus-2 infection. An emerging disease? Infect Dis Clin North Am 1998;12(1):47-61
19. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med 1991;324(18):1247-52
20. Nahmias AJ. Neonatal HSV infection Part I: continuing challenges. Herpes 2004;11(2):33-7
21. Spruance SL, Overall JC Jr, Kern ER, et al. The natural history of recurrent herpes simplex labialis: implications for antiviral therapy. N Engl J Med 1977;297(2):69-75
22. Lafferty WE, Coombs RW, Benedetti J, et al. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. N Engl J Med 1987;316(23):1444-9
23. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35(5):435-45
24. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185(1):45-52
25. Cunningham AL, Dwyer DE. The pathogenesis underlying the interaction of HIV and herpes simplex virus after co-infection. J HIV Ther 2004;9(1):9-13
26. Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20(1):73-83
27. Reynolds SJ, Quinn TC. Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2. Infect Dis Clin North Am 2005;19(2):415-25
28. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007;356(8):790-9
29. Ouedraogo A, Nagot N, Vergne L, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006;20(18):2305-13
30. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350(1):11-20
31. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12(1):33-9
32. Wald A, Langenberg AG, Krantz E, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005;143(10):707-13
33. Wald A, Selke S, Warren T et al. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex Transm Dis 2006;33(9):529-33
34. Mark KE, Corey L, Meng TC, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 2007;195(9):1324-31
35. Stanberry LR, Cunningham AL, Mindel A, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000;30(3):549-66
36. Sheffield JS, Hollier LM, Hill JB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol 2003;102(6):1396-403
37. Garnett GP, Dubin G, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 2004;80(1):24-9 • Uses mathematical models to explore the impact on public health of vaccines with different effects on the natural history of HSV disease.
38. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev 2003;16(1):96-113
39. Bourne N, Bravo FJ, Francotte M, et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003;187(4):542-9
40. Lasky LA, Dowbenko DJ. DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2. DNA 1984;3(1):23-9
41. Eisenberg RJ, Ponce De Leon M, Cohen GH. Comparative structural analysis of glycoprotein gD of herpes simplex virus types 1 and 2. J Virol 1980;35(2):428-35
42. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In: Field's Virology. 4th edition. Knipe DM, Howley PM, editors. Williams & Willems; 2001. p. 2399-459
43. Sawtell NM. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 1998;72(8):6888-92
44. Sawtell NM, Thompson RL, Stanberry LR, Bernstein DI. Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo. J Infect Dis 2001;184(8):964-71
45. Lakeman AD, Nahmias AJ, Whitley RJ. Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis 1986;13(2):61-6
46. Stanberry LR. Genital and perinatal herpes simplex virus infections: proplylactic vaccines. In: Sexually Transmitted Diseases: Vaccines, Prevention and Control. Stanberry LR, Bernstein DI, editors. Academic Press; 2000. p. 187-216
47. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158(3):602-14
48. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990;162(2):313-21
49. Spector FC, Kern ER, Palmer J, et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis 1998;177(5):1143-54
50. Prichard MN, Kaiwar R, Jackman WT, et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine 2005;23(46-47):5424-31
51. Wachsman M, Kulka M, Smith CC, Aurelian L. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine 2001;19(15-16):1879- 90
52. Aurelian L. Herpes simplex virus type 2 vaccines: new ground for optimism? Clin Diagn Lab Immunol 2004;11(3):437-45
53. Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997;175(1):16-25
54. Morrison LA, Knipe DM. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology 1997;239(2):315-26
55. Hoshino Y, Dalai SK, Wang K, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 2005;79(1):410-8
56. DA Costa XJ, Morrison LA, Knipe DM. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Virology 2001;288(2):256-63
57. Dudek T, Knipe DM. Replication-defective viruses as vaccines and vaccine vectors. Virology 2006;344(1):230-9
58. Roberts JS, Uttridge JA, Hickling JK, Al E. Safety tolerability and viral containment of a disabled infectious single cycle HSV-2 vaccine evaluated in phase 1 clinical trials in HSV-2 seropositive and seronegative Volumenteers. In: 8th International Congress on Infectious Diseases. Boston, MA; 1998
59. Bernstein DI. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine 2000;18(14):1351-8
60. Orr MT, Orgun NN, Wilson CB, Way SS. Cutting Edge: Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 2007;178(8):4731-5
61. Gallichan WS, Rosenthal KL. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995;13(16):1589-95
62. Heineman TC, Connelly BL, Bourne N, et al. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol 1995;69(12):8109-13
63. Karem KL, Bowen J, Kuklin N, Rouse BT. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens. J Gen Virol 1997;78(Pt 2):427-34
64. Pachuk CJ, Arnold R, Herold K, et al. Humoral and cellular immune responses to herpes simplex virus-2 glycoprotein D generated by facilitated DNA immunization of mice. Curr Top Microbiol Immunol 1998;226:79-89
65. Kim TW, Hung CF, Kim JW, et al. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity. Hum Gene Ther 2004;15(2):167-77
66. Meseda CA, Schmeisser F, Pedersen R, et al. DNA immunization with a herpes simplex virus 2 bacterial artificial chromosome. Virology 2004;318(1):420-8
67. Strasser JE, Arnold RL, Pachuk C, et al. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis 2000;182(5):1304-10
68. Rajcani J, Mosko T, Rezuchova I. Current developments in viral DNA vaccines: shall they solve the unsolved? Rev Med Virol 2005;15(5):303-25
69. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Rev Med Virol 2002;12(5):279-96
70. Pushko P, Parker M, Ludwig GV, et al. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997;239(2):389-401
71. Long D, Kowalski J, Natuk R, et al. Immunization of mice, guinea pigs, and non-human primates with alphavirus replicons expressing the herpes simplex virus type 2 glycoprotein D. In: 3rd Annual Conference on Vaccine Research; 2000
72. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 1999;17(13-14):1681-9
73. Jones CA, Cunningham AL. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 2004;11(1):12-7
74. Meignier B. Vaccination against herpes simplex virus infections. In: Therpesviruses, Plenum. Roizman B, Lopez C, editors. 1995. p. 256-312
75. Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med 1995;122(12):889-98
76. Kohl S, Charlebois ED, Sigouroudinia M, et al. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J Infect Dis 2000;181(1):335-9
77. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999;282(4):331-40
78. Leroux-Roels G, Moreau E, Desombere I. Persistence of humoral and cellular immune response and booster effect following vaccination with the herpes simplex 9gD2t candidate vaccine with MPL. In: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; Orlando, FL; 1994
79. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21):1652-61 •• Original study reporting on the first and only vaccine with efficacy against HSV genital disease.
80. Bernstein DI, Aoki FY, Tyring SK, et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis 2005;40(9):1271-81 • Original report on the safety of the GSK HSV vaccine.
81. Ashley RL, Crisostomo FM, Doss M, et al. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine. J Infect Dis 1998;178(1):1-7
82. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 2004;11(Suppl 3):161A-169A
83. Goel N, Rong Q, Zimmerman D, Rosenthal KS. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 2003;21(27-30):4410-20
84. Kumaraguru U, Gierynska M, Norman S, et al. Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infection. J Virol 2002;76(1):136-41
85. Benmohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect Dis 2002;2(7):425-31
86. Bettahi I, Zhang X, Afifi RE, Benmohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol 2006;19(2):220-36
87. Zhang X, Issagholian A, Berg EA, et al. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J Virol 2005;79(24):15289-301
88. Mays RM, Zimet GD. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis 2004;31(7):428-32
89. Siegel RM, Baker RC, Kotagal UR, Balistreri WF. Hepatitis B vaccine use in Cincinnati: a community's response to the AAP recommendation of universal hepatitis B immunization. J Natl Med Assoc 1994;86(6):444-8
90. Britto CD, Atherton HD, Dewitt TG. Immunizing adolescents in private practice: Lessons learned from Hepatitis B. Prev Med Managed Care 2001;2:127-34
91. Zimet GD, Mays RM, Winston Y, et al. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000;9(1):47-50
92. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 2004;58(7):1405-13
93. Zimet GD, Perkins SM, Sturm LA, et al. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 2005;37(3):179-86 • Excellent study and discussion on parent's opinion of having their child immunized for sexually transmitted infections.
94. Fowler SL, Dickey M, Kern P, et al. Perceptions of parents seeking an experimental herpes simplex vaccine for their adolescent and preadolescent daughters. Pediatr Infect Dis J 2006;25(8):747-8
95. Kahn JA, Rosenthal SL, Hamann T, Bernstein DI. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003;14(5):300-6
96. Rosenthal SL, Lewis LM, Succop PA, et al. College students' attitudes regarding vaccination to prevent genital herpes. Sex Transm Dis 1999;26(8):438-43
97. Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 2003;30(10):774-8
98. Hoover DR, Carfioli B, Moench EA. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 2000;21(5):375-91
99. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis 2000;27(1):49-52
100. Zimet GD, Fortenberry JD, Fife KH, et al. Acceptability of genital herpes immunization. The role of health beliefs and health behaviors. Sex Transm Dis 1997;24(10):555-60 • A discussion of the complex factors associated with being immunized against genital herpes.
101. Lewis LM, Stanberry LR, Rosenthal SL, et al. Attitudes regarding vaccinations of STDs and other diseases. Im J STD AIDS 2000;11(3):170-2
102. Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 2005;37(6):511-6
103. Tung CS, Middleman AB. An evaluation of school-level factors used in a successful school-based hepatitis B immunization initiative. J Adolesc Health 2005;37(1):61-8
104. Schaffer SJ, Humiston SG, Shone LP, et al. Adolescent immunization practices: a national survey of US physicians. Arch Pediatr Adolesc Med 2001;155(5):566-71
105. Humiston SG, Rosenthal SL. Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J 2005;24(6 Suppl):S134-40
106. Waller J, Marlow LA, Wardle J. Mothers' attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomarkers Prev 2006;15(7):1257-61